Elevated levels of interleukin-9 in the serum of bullous pemphigoid: possible association with the pathogenicity of bullous pemphigoid.
autoantibody
autoimmune bullous disease
basement membrane
cytokine
pemphigoid
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
31
12
2022
accepted:
30
05
2023
medline:
5
7
2023
pubmed:
3
7
2023
entrez:
3
7
2023
Statut:
epublish
Résumé
Bullous pemphigoid (BP) is an autoimmune subepidermal blistering disease (sAIBD). In addition to disease causing autoantibodies, several leukocyte subsets, including mast cells and eosinophils, play key roles in mediating skin inflammation. Detailed immunophenotyping and, more recently, the therapeutic effects of interleukin-4 (IL-4) receptor alpha inhibition in BP pointed to a prominent role of T helper 2 (Th2) cells. Among other cell types, IL-9 is expressed by Th2 and mast cells and potentially drives allergic, Th2-dominated inflammation. Although cytokines in BP have been relatively well investigated, the role of IL-9 has remained enigmatic. This study aimed to evaluate the effect of IL-9 in BP. Serum IL-9 levels were significantly elevated in patients with BP and decreased upon induction of remission. Serum IL-9 levels were not elevated in epidermolysis bullosa acquisita, another sAIBD. The time-course analysis using serum sets from four patients with BP revealed that serum IL-9 was a sensitive biomarker of BP. IL-9-positive cells infiltrated dominantly in BP lesions, especially in the blister fluid, and Th9 cells were abundant. Therefore, IL-9 was elevated in the serum and lesions of BP, which could be a biomarker of BP.
Identifiants
pubmed: 37398641
doi: 10.3389/fimmu.2023.1135002
pmc: PMC10311483
doi:
Substances chimiques
Interleukin-9
0
Biomarkers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1135002Informations de copyright
Copyright © 2023 Koga, Teye, Sugawara, Tsutsumi, Ishii and Nakama.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Dermatol Sci. 2015 Apr;78(1):5-10
pubmed: 25797172
Br J Dermatol. 2020 May;182(5):1221-1227
pubmed: 31330562
Front Immunol. 2018 Feb 28;9:386
pubmed: 29541076
Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12885-90
pubmed: 19433802
Front Immunol. 2021 Aug 24;12:718073
pubmed: 34504496
Semin Immunopathol. 2017 Jan;39(1):47-54
pubmed: 27896634
Exp Dermatol. 2011 Dec;20(12):1022-4
pubmed: 22017210
Clin Cancer Res. 2016 Jul 1;22(13):3328-39
pubmed: 26851186
Front Immunol. 2019 Jun 04;10:1238
pubmed: 31275298
Br J Dermatol. 2017 Jul;177(1):141-151
pubmed: 27716903
Clin Dermatol. 2013 Jul-Aug;31(4):391-399
pubmed: 23806156
Nat Med. 2012 Aug;18(8):1248-53
pubmed: 22772464
J Allergy Clin Immunol. 2015 Aug;136(2):433-40.e1
pubmed: 25746972
Front Med (Lausanne). 2019 Jan 10;5:362
pubmed: 30687710
J Autoimmun. 2019 Jan;96:104-112
pubmed: 30219389
Ann N Y Acad Sci. 2012 Jan;1247:56-68
pubmed: 22235761
PLoS One. 2013;8(1):e51752
pubmed: 23335955
Clin Exp Immunol. 2014 Jan;175(1):25-31
pubmed: 24032555
J Invest Dermatol. 2020 Sep;140(9):1713-1722.e9
pubmed: 32057838
Eur J Immunol. 2015 May;45(5):1462-70
pubmed: 25678008
Allergy. 2017 Jul;72(7):1105-1113
pubmed: 28135772
Nat Rev Immunol. 2015 May;15(5):295-307
pubmed: 25848755
Lancet. 2013 Jan 26;381(9863):320-32
pubmed: 23237497
J Clin Invest. 2006 Nov;116(11):2892-900
pubmed: 17024247
Nat Rev Immunol. 2010 Oct;10(10):683-7
pubmed: 20847745